Astrazeneca (AZN) Finished Goods (2015 - 2025)

Astrazeneca has reported Finished Goods for 11 years, with the latest figure at $1.9 billion in Q4 2025.

• On a quarterly basis, Finished Goods rose 26.76% year-over-year to $1.9 billion in Q4 2025; TTM through Dec 2025 was $1.9 billion, a 26.76% increase from a year earlier, with the FY2025 full-year figure at $1.9 billion, up 26.76% from the prior year.
• Finished Goods was $1.9 billion for Q4 2025 at Astrazeneca, up from $1.5 billion in the prior quarter.
• The five-year high for Finished Goods was $2.0 billion in Q4 2021, with the low at $1.4 billion in Q4 2022.
• Average Finished Goods over 5 years is $1.7 billion, with a median of $1.6 billion recorded in 2023.
• The sharpest annual moves came in 2021 and 2022: Finished Goods soared 40.6% in 2021, then fell 29.77% in 2022.
• Over 5 years, Finished Goods stood at $2.0 billion in 2021, then declined by 29.77% to $1.4 billion in 2022, then increased by 10.97% to $1.6 billion in 2023, then dropped by 3.25% to $1.5 billion in 2024, then gained by 26.76% to $1.9 billion in 2025.
• The last three Finished Goods figures came in at $1.9 billion (Q4 2025), $1.5 billion (Q4 2024), and $1.6 billion (Q4 2023), per Business Quant data.